Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-gtxcr Total loading time: 0 Render date: 2024-04-19T22:38:46.641Z Has data issue: false hasContentIssue false

Chapter 7 - Psychopharmacology of Autism Spectrum Disorders

Published online by Cambridge University Press:  18 January 2019

By
Lindsey Mooney ,
Cara Fosdick  and
Craig A. Erickson
Edited by
Fred R. Volkmar
Fred R. Volkmar
Affiliation:
Yale University, Connecticut
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Autism and Pervasive Developmental Disorders , pp. 158 - 175
Publisher: Cambridge University Press
Print publication year: 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Accordino, R. E., Kidd, C., Politte, L. C., Henry, C. A., & McDougle, C. J. (2016). Psychopharmacological interventions in autism spectrum disorder. Expert Opin Pharmacother, 17(7), 937–952. doi: 10.1517/14656566.2016.1154536CrossRefGoogle ScholarPubMed
Adler, B. A., Wink, L. K., Early, M., et al. (2015). Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: a chart review study. Autism, 19(1), 102–106. doi: 10.1177/1362361314524641CrossRefGoogle ScholarPubMed
Aman, M., Rettiganti, M., Nagaraja, H. N., et al. (2015). Tolerability, safety, and benefits of risperidone in children and adolescents with autism: 21-month follow-up after 8-week placebo-controlled trial. J Child Adolesc Psychopharmacol, 25(6), 482–493. doi: 10.1089/cap.2015.0005Google Scholar
Aman, M. G., Findling, R. L., Hardan, A. Y., et al. (2017). Safety and efficacy of memantine in children with autism: randomized, placebo-controlled study and open-label extension. J Child Adolesc Psychopharmacol, 27(5), 403–412. doi: 10.1089/cap.2015.0146CrossRefGoogle ScholarPubMed
Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 5, 485–491.Google Scholar
Anagnostou, E., Soorya, L., Chaplin, W., et al. (2012). Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol Autism, 3(1), 16. doi: 10.1186/2040-2392-3-16CrossRefGoogle ScholarPubMed
Anderson, L. T., Campbell, M., Adams, P., et al. (1989). The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord, 19(2), 227–239.CrossRefGoogle ScholarPubMed
Anderson, L. T., Campbell, M., Grega, D. M., et al. (1984). Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry, 141(10), 1195–1202. doi: 10.1176/ajp.141.10.1195Google Scholar
Arnold, L. E., Aman, M. G., Cook, A. M., et al. (2006). Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry, 45(10), 1196–1205. doi: 10.1097/01.chi.0000231976.28719.2aGoogle Scholar
Beherec, L., Lambrey, S., Quilici, G., et al. (2011). Retrospective review of clozapine in the treatment of patients with autism spectrum disorder and severe disruptive behaviors. J Clin Psychopharmacol, 31(3), 341–344. doi: 10.1097/JCP.0b013e318218f4a1Google Scholar
Blackmer, A. B., & Feinstein, J. A. (2016). Management of sleep disorders in children with neurodevelopmental disorders: a review. Pharmacotherapy, 36(1), 84–98. doi: 10.1002/phar.1686Google Scholar
Buitelaar, J. K., van der Gaag, R. J., & van der Hoeven, J. (1998). Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study. J Clin Psychiatry, 59(2), 56–59.Google Scholar
Campbell, M., Anderson, L. T., & Meier, M. (1979). A comparison of haloperidol, behavior therapy, and their interaction in autistic children [proceedings]. Psychopharmacol Bull, 15(2), 84–86.Google ScholarPubMed
Campbell, M., Anderson, L. T., Meier, M., et al. (1978). A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry, 17(4), 640–655.CrossRefGoogle ScholarPubMed
Chen, N. C., Bedair, H. S., McKay, B., Bowers, M. B. Jr., & Mazure, C. (2001). Clozapine in the treatment of aggression in an adolescent with autistic disorder. J Clin Psychiatry, 62(6), 479–480.Google Scholar
Corson, A. H., Barkenbus, J. E., Posey, D. J., Stigler, K. A., & McDougle, C. J. (2004). A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry, 65(11), 1531–1536.CrossRefGoogle ScholarPubMed
Cortesi, F., Giannotti, F., Sebastiani, T., Panunzi, S., & Valente, D. (2012). Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial. J Sleep Res, 21(6), 700–709. doi: 10.1111/j.1365-2869.2012.01021.xCrossRefGoogle ScholarPubMed
Couturier, J. L., & Nicolson, R. (2002). A retrospective assessment of citalopram in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol, 12(3), 243–248. doi: 10.1089/104454602760386932Google Scholar
Dean, O. M., Gray, K. M., Villagonzalo, K. A., et al. (2016). A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder. Aust N Z J Psychiatry. doi: 10.1177/0004867416652735Google Scholar
Dominick, K., Wink, L. K., McDougle, C. J., & Erickson, C. A. (2015). A retrospective naturalistic study of ziprasidone for irritability in youth with autism spectrum disorder. J Child Adolesc Psychopharmacol, 25(5), 397–401. doi: 10.1089/cap.2014.0111CrossRefGoogle ScholarPubMed
Erickson, C. A., Early, M., Stigler, K. A., et al. (2011). An open-label naturalistic pilot study of acamprosate in youth with autistic disorder. J Child Adolesc Psychopharmacol, 21(6), 565–569. doi: 10.1089/cap.2011.0034CrossRefGoogle ScholarPubMed
Erickson, C. A., Wink, L. K., Early, M. C., et al. (2014). Brief report: Pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder. J Autism Dev Disord, 44(4), 981–987. doi: 10.1007/s10803-013-1943-3Google Scholar
Findling, R. L., McNamara, N. K., Gracious, B. L., et al. (2004). Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol, 14(2), 287–294. doi: 10.1089/1044546041649129CrossRefGoogle ScholarPubMed
Fitzpatrick, S. E., Srivorakiat, L., Wink, L. K., Pedapati, E. V., & Erickson, C. A. (2016). Aggression in autism spectrum disorder: presentation and treatment options. Neuropsychiatr Dis Treat, 12, 1525–1538. doi: 10.2147/NDT.S84585Google Scholar
Ghanizadeh, A., Sahraeizadeh, A., & Berk, M. (2014). A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry Hum Dev, 45(2), 185–192. doi: 10.1007/s10578-013-0390-xCrossRefGoogle ScholarPubMed
Ghuman, J. K., Aman, M. G., Lecavalier, L., et al. (2009). Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders. J Child Adolesc Psychopharmacol, 19(4), 329–339. doi: 10.1089/cap.2008.0137Google Scholar
Gobbi, G., & Pulvirenti, L. (2001). Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behaviour. J Psychiatry Neurosci, 26(4), 340–341.Google Scholar
Goldman, S. E., Richdale, A. L., Clemons, T., & Malow, B. A. (2012). Parental sleep concerns in autism spectrum disorders: variations from childhood to adolescence. J Autism Dev Disord, 42(4), 531–538. doi: 10.1007/s10803-011-1270-5Google Scholar
Golubchik, P., Sever, J., & Weizman, A. (2011). Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial. Clin Neuropharmacol, 34(6), 216–219. doi: 10.1097/WNF.0b013e31823349acCrossRefGoogle ScholarPubMed
Gordon, I., Jack, A., Pretzsch, C. M., et al. (2016). Intranasal oxytocin enhances connectivity in the neural circuitry supporting social motivation and social perception in children with autism. Sci Rep, 6, 35054. doi: 10.1038/srep35054Google Scholar
Greenhill, L. L., Swanson, J. M., Vitiello, B., et al. (2001). Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry, 40(2), 180–187. doi: 10.1097/00004583-200102000-00012Google Scholar
Handen, B. L., Aman, M. G., Arnold, L. E., et al. (2015). Atomoxetine, parent training, and their combination in children with autism spectrum disorder and attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry, 54(11), 905–915. doi: 10.1016/j.jaac.2015.08.013Google Scholar
Handen, B. L., Johnson, C. R., & Lubetsky, M. (2000). Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord, 30(3), 245–255.Google Scholar
Handen, B. L., Sahl, R., & Hardan, A. Y. (2008). Guanfacine in children with autism and/or intellectual disabilities. J Dev Behav Pediatr, 29(4), 303–308. doi: 10.1097/DBP.0b013e3181739b9dCrossRefGoogle ScholarPubMed
Hardan, A. Y., Fung, L. K., Libove, R. A., et al. (2012). A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry, 71(11), 956–961. doi: 10.1016/j.biopsych.2012.01.014CrossRefGoogle ScholarPubMed
Harfterkamp, M., van de Loo-Neus, G., Minderaa, R. B., et al. (2012). A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry, 51(7), 733–741. doi: 10.1016/j.jaac.2012.04.011Google Scholar
Hastings, R. P., Kovshoff, H., Ward, N. J., et al. (2005). Systems analysis of stress and positive perceptions in mothers and fathers of pre-school children with autism. J Autism Dev Disord, 35(5), 635–644. doi: 10.1007/s10803-005-0007-8Google Scholar
Hellings, J. A., Weckbaugh, M., Nickel, E. J., et al. (2005). A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol, 15(4), 682–692. doi: 10.1089/cap.2005.15.682Google Scholar
Hirota, T., Veenstra-Vanderweele, J., Hollander, E., & Kishi, T. (2014). Antiepileptic medications in autism spectrum disorder: a systematic review and meta-analysis. J Autism Dev Disord, 44(4), 948–957. doi: 10.1007/s10803-013-1952-2CrossRefGoogle ScholarPubMed
Hollander, E., Chaplin, W., Soorya, L., et al. (2010). Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology, 35(4), 990–998. doi: 10.1038/npp.2009.202CrossRefGoogle ScholarPubMed
Hollander, E., Soorya, L., Wasserman, S., et al. (2006). Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. Int J Neuropsychopharmacol, 9(2), 209–213. doi: 10.1017/s1461145705005791Google Scholar
Hollander, E., Wasserman, S., Swanson, E. N., et al. (2006). A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol, 16(5), 541–548.Google Scholar
Jaselskis, C. A., Cook, E. H. Jr., Fletcher, K. E., & Leventhal, B. L. (1992). Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol, 12(5), 322–327.CrossRefGoogle ScholarPubMed
King, B. H., Hollander, E., Sikich, L., et al. (2009). Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry, 66(6), 583–590. doi: 66/6/583 [pii] 10.1001/archgenpsychiatry.2009.30CrossRefGoogle ScholarPubMed
Kowalski, J. L., Wink, L. K., Blankenship, K., et al. (2011). Paliperidone palmitate in a child with autistic disorder. J Child Adolesc Psychopharmacol, 21(5), 491–493. doi: 10.1089/cap.2011.0035Google Scholar
Krishnaswami, S., McPheeters, M. L., & Veenstra-Vanderweele, J. (2011). A systematic review of secretin for children with autism spectrum disorders. Pediatrics, 127(5), e1322–1325. doi: 10.1542/peds.2011-0428Google Scholar
Lambrey, S., Falissard, B., Martin-Barrero, M., et al. (2010). Effectiveness of clozapine for the treatment of aggression in an adolescent with autistic disorder. J Child Adolesc Psychopharmacol, 20(1), 79–80. doi: 10.1089/cap.2009.0057CrossRefGoogle Scholar
Lecavalier, L., Leone, S., & Wiltz, J. (2006). The impact of behaviour problems on caregiver stress in young people with autism spectrum disorders. J Intellect Disabil Res, 50(Pt 3), 172–183. doi: 10.1111/j.1365-2788.2005.00732.xGoogle Scholar
Leyfer, O. T., Folstein, S. E., Bacalman, S., et al. (2006). Comorbid psychiatric disorders in children with autism: interview development and rates of disorders. J Autism Dev Disord, 36(7), 849–861. doi: 10.1007/s10803-006-0123-0Google Scholar
Loebel, A., Brams, M., Goldman, R. S., et al. (2016). Lurasidone for the Treatment of Irritability Associated with Autistic Disorder. J Autism Dev Disord, 46(4), 1153–1163. doi: 10.1007/s10803-015-2628-xCrossRefGoogle ScholarPubMed
Malone, R. P., Cater, J., Sheikh, R. M., Choudhury, M. S., & Delaney, M. A. (2001). Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry, 40(8), 887–894.Google Scholar
Malone, R. P., Delaney, M. A., Hyman, S. B., & Cater, J. R. (2007). Ziprasidone in adolescents with autism: an open-label pilot study. J Child Adolesc Psychopharmacol, 17(6), 779–790. doi: 10.1089/cap.2006.0126Google Scholar
Malow, B. A., Byars, K., Johnson, K., et al., Sleep Committee of the Autism Treatment, N. (2012). A practice pathway for the identification, evaluation, and management of insomnia in children and adolescents with autism spectrum disorders. Pediatrics, 130(2), S106–124. doi: 10.1542/peds.2012-0900IGoogle Scholar
Marcus, R. N., Owen, R., Kamen, L., et al. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry, 48(11), 1110–1119. doi: 10.1097/CHI.0b013e3181b76658Google Scholar
Marcus, R. N., Owen, R., Manos, G., et al. (2011). Aripiprazole in the treatment of irritability in pediatric patients (aged 6–17 years) with autistic disorder: results from a 52-week, open-label study. J Child Adolesc Psychopharmacol, 21(3), 229–236. doi: 10.1089/cap.2009.0121Google Scholar
Marcus, R. N., Owen, R., Manos, G., et al. (2011). Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. J Clin Psychiatry, 72(9), 1270–1276. doi: 10.4088/JCP.09m05933Google Scholar
Martin, A., Koenig, K., Anderson, G. M., & Scahill, L. (2003). Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study. J Autism Dev Disord, 33(1), 77–85.Google Scholar
McClellan, L., Dominick, K. C., Pedapati, E. V., Wink, L. K., & Erickson, C. A. (2017). Lurasidone for the treatment of irritability and anger in autism spectrum disorders. Expert Opin Investig Drugs, 26(8), 985–989. doi: 10.1080/13543784.2017.1353600Google Scholar
McCracken, J. T., McGough, J., Shah, B., et al. (2002). Risperidone in children with autism and serious behavioral problems. N Engl J Med, 347(5), 314–321. doi: 10.1056/NEJMoa013171CrossRefGoogle ScholarPubMed
McDougle, C. J., Holmes, J. P., Carlson, D. C., et al. (1998). A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry, 55(7), 633–641.Google Scholar
McDougle, C. J., Naylor, S. T., Cohen, D. J., et al. (1996). A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry, 53(11), 1001–1008.Google Scholar
McKnight, R. F., Adida, M., Budge, K., et al. (2012). Lithium toxicity profile: a systematic review and meta-analysis. Lancet, 379(9817), 721–728. doi: 10.1016/s0140-6736(11)61516-xGoogle Scholar
Ming, X., Gordon, E., Kang, N., & Wagner, G. C. (2008). Use of clonidine in children with autism spectrum disorders. Brain Dev, 30(7), 454–460. doi: 10.1016/j.braindev.2007.12.007Google Scholar
Minshawi, N. F., Wink, L. K., Shaffer, R., et al. (2016). A randomized, placebo-controlled trial of D-cycloserine for the enhancement of social skills training in autism spectrum disorders. Mol Autism, 7, 2. doi: 10.1186/s13229-015-0062-8Google Scholar
Namerow, L., Thomas, P., Bostic, J. Q., Prince, J., & Monuteaux, M. C. (2003). Use of citalopram in pervasive developmental disorders. J Dev Behav Pediatr, 24(2), 104–108.CrossRefGoogle ScholarPubMed
Owen, R., Sikich, L., Marcus, R. N., et al. (2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124(6), 1533–1540. doi: 124/6/1533 [pii]10.1542/peds.2008-3782Google Scholar
Politte, L. C. & McDougle, C. J. (2014). Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl), 231(6), 1023–1036. doi: 10.1007/s00213-013-3068-yCrossRefGoogle ScholarPubMed
Posey, D., Stigler, K., Erickson, C., et al. (2007). A double-blind placebo-controlled study of D-cycloserine in children with autistic disorder. Paper presented at the American College of Neuropsychopharmacology 46th Annual Meeting, Boca Raton, Florida.Google Scholar
Posey, D. J., Kem, D. L., Swiezy, N. B., et al. (2004). A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry, 161(11), 2115–2117. doi: 10.1176/appi.ajp.161.11.2115Google Scholar
Posey, D. J., Stigler, K. A., Erickson, C. A., & McDougle, C. J. (2008). Antipsychotics in the treatment of autism. J Clin Invest, 118(1), 6–14. doi: 10.1172/jci32483Google Scholar
Quintana, H., Birmaher, B., Stedge, D., et al. (1995). Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord, 25(3), 283–294.Google Scholar
Reichow, B., Volkmar, F. R., & Bloch, M. H. (2013). Systematic review and meta-analysis of pharmacological treatment of the symptoms of attention-deficit/hyperactivity disorder in children with pervasive developmental disorders. J Autism Dev Disord, 43(10), 2435–2441. doi: 10.1007/s10803-013-1793-zGoogle Scholar
Research Units on Pediatric Psychopharmacology Autism, N. (2005). Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry, 62(11), 1266–1274. doi: 10.1001/archpsyc.62.11.1266Google Scholar
Roy, A., Roy, M., Deb, S., Unwin, G., & Roy, A. (2015). Are opioid antagonists effective in attenuating the core symptoms of autism spectrum conditions in children: a systematic review. J Intellect Disabil Res, 59(4), 293–306. doi: 10.1111/jir.12122Google Scholar
Scahill, L., McCracken, J. T., King, B. H., et al., Research Units on Pediatric Psychopharmacology Autism, N. (2015). Extended-release guanfacine for hyperactivity in children with autism spectrum disorder. Am J Psychiatry, 172(12), 1197–1206. doi: 10.1176/appi.ajp.2015.15010055Google Scholar
Schade, S. & Paulus, W. (2016). D-Cycloserine in neuropsychiatric diseases: a systematic review. Int J Neuropsychopharmacol, 19(4). doi: 10.1093/ijnp/pyv102Google Scholar
Serret, S., Thummler, S., Dor, E., et al. (2015). Lithium as a rescue therapy for regression and catatonia features in two SHANK3 patients with autism spectrum disorder: case reports. BMC Psychiatry, 15, 107. doi: 10.1186/s12888-015-0490-1Google Scholar
Shea, S., Turgay, A., Carroll, A., et al. (2004). Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114(5), e634–641. doi: 10.1542/peds.2003-0264-FGoogle Scholar
Siegel, M., Beresford, C. A., Bunker, M., et al. (2014). Preliminary investigation of lithium for mood disorder symptoms in children and adolescents with autism spectrum disorder. J Child Adolesc Psychopharmacol, 24(7), 399–402. doi: 10.1089/cap.2014.0019Google Scholar
Singh, K., Connors, S. L., Macklin, E. A., et al. (2014). Sulforaphane treatment of autism spectrum disorder (ASD). Proc Natl Acad Sci U S A, 111(43), 15550–15555. doi: 10.1073/pnas.1416940111Google Scholar
Stigler, K. A., Desmond, L. A., Posey, D. J., Wiegand, R. E., & McDougle, C. J. (2004). A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. J Child Adolesc Psychopharmacol, 14(1), 49–56. doi: 10.1089/104454604773840481Google Scholar
Stigler, K. A., & McDougle, C. J. (2008). Pharmacotherapy of irritability in pervasive developmental disorders. Child Adolesc Psychiatr Clin N Am, 17(4), 739–752. doi: S1056-4993(08)00046-1 [pii] 10.1016/j.chc.2008.06.002CrossRefGoogle ScholarPubMed
Stigler, K. A., Mullett, J. E., Erickson, C. A., Posey, D. J., & McDougle, C. J. (2012). Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology (Berl), 223(2), 237–245. doi: 10.1007/s00213-012-2711-3Google Scholar
Urbano, M., Okwara, L., Manser, P., Hartmann, K., & Deutsch, S. I. (2015). A trial of d-cycloserine to treat the social deficit in older adolescents and young adults with autism spectrum disorders. J Neuropsychiatry Clin Neurosci, 27(2), 133–138. doi: 10.1176/appi.neuropsych.13070155Google Scholar
Urbano, M., Okwara, L., Manser, P., et al. (2014). A trial of D-cycloserine to treat stereotypies in older adolescents and young adults with autism spectrum disorder. Clin Neuropharmacol, 37(3), 69–72. doi: 10.1097/WNF.0000000000000033Google Scholar
Vasa, R. A., Carroll, L. M., Nozzolillo, A. A., et al. (2014). A systematic review of treatments for anxiety in youth with autism spectrum disorders. J Autism Dev Disord, 44(12), 3215–3229. doi: 10.1007/s10803-014-2184-9Google Scholar
Veenstra-VanderWeele, J., Cook, E. H., King, B. H., et al. (2017). Arbaclofen in children and adolescents with autism spectrum disorder: a randomized, controlled, phase 2 trial. Neuropsychopharmacology, 42(7), 1390–1398. doi: 10.1038/npp.2016.237CrossRefGoogle ScholarPubMed
Wasdell, M. B., Jan, J. E., Bomben, M. M., et al. (2008). A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pineal Res, 44(1), 57–64. doi: 10.1111/j.1600-079X.2007.00528.xGoogle Scholar
Williams, K., Brignell, A., Randall, M., Silove, N., & Hazell, P. (2013). Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev (8), Cd004677. doi: 10.1002/14651858.CD004677.pub3Google Scholar
Wink, L. K., Adams, R., Wang, Z., et al. (2016). A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder. Mol Autism, 7, 26. doi: 10.1186/s13229-016-0088-6Google Scholar
Wink, L. K., Badran, I., Pedapati, E. V., et al. (2016). Clozapine for drug-refractory irritability in individuals with developmental disability. J Child Adolesc Psychopharmacol, 26(9), 843–846. doi: 10.1089/cap.2015.0216Google Scholar
Wink, L. K., Early, M., Schaefer, T., et al. (2014). Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole. J Child Adolesc Psychopharmacol, 24(2), 78–82. doi: 10.1089/cap.2013.0099CrossRefGoogle ScholarPubMed
Wink, L. K., Minshawi, N. F., Shaffer, R. C., et al. (2017). d-Cycloserine enhances durability of social skills training in autism spectrum disorder. Mol Autism, 8, 2. doi: 10.1186/s13229-017-0116-1Google Scholar
Wright, B., Sims, D., Smart, S., et al. (2011). Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial. J Autism Dev Disord, 41(2), 175–184. doi: 10.1007/s10803-010-1036-5Google Scholar
Yatawara, C. J., Einfeld, S. L., Hickie, I. B., Davenport, T. A., & Guastella, A. J. (2016). The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial. Mol Psychiatry, 21(9), 1225–1231. doi: 10.1038/mp.2015.162Google Scholar
Yoon, Y., Wink, L. K., Pedapati, E. V., Horn, P. S., & Erickson, C. A. (2016). Weight gain effects of second-generation antipsychotic treatment in autism spectrum disorder. J Child Adolesc Psychopharmacol, 26(9), 822–827. doi: 10.1089/cap.2016.0049Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×